drugset / Trial / NCT06711471
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.
Timeline
- Start
- 2024-11-14
- Primary completion
- 2026-11-13
- Completion
- 2027-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tipiracil | Small molecule | — | Oral |
| Subject | Trifluridine | Small molecule | 35 mg/m2 | Oral |